|
1）Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science. 1997; 278: 1626-9
|
|
|
|
2）Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J Exp Med. 1998; 188: 1521-8
|
|
|
|
|
|
3）Spada FM, Koezuka Y, Porcelli SA. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. J Exp Med. 1998; 188: 1529-34
|
|
|
|
|
|
4）Smyth MJ, Crowe NY, Pellicci DG, et al. Sequential production of interferon-γ by NK1. 1 (＋) T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood. 2002; 99: 1259-66
|
|
|
|
|
|
5）Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells byα-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med. 2003; 198: 267-79
|
|
|
|
|
|
6）Motohashi S, Kobayashi S, Ito T, et al. Preserved IFN-γ production of circulating Vα24 NKT cells in primary lung cancer patients. Int J Cancer. 2002; 102: 159-65
|
|
|
|
|
|
7）Yanagisawa K, Seino K, Ishikawa Y, et al. Impaired proliferative response of Vα24 NKT cells from cancer patients againstα- galactosylceramide. J Immunol. 2002; 168: 6494-9
|
|
|
|
|
|
8）Fujii S, Shimizu K, Klimek V, et al. Severe and selective deficiency of interferon-γ-producing invariant natural killer T cells in patients with myelodysplastic syndromes. Br J Haematol. 2003; 122: 617-22
|
|
|
|
|
|
9）Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med. 2003; 197: 1667-76
|
|
|
|
|
|
10）Dhodapkar KM, Cirignano B, Chamian F, et al. Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion. Int J Cancer. 2004; 109: 893-9
|
|
|
|
|
|
11）Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002; 8: 3702-9
|
|
|
|
|
|
12）Ishikawa A, Motohashi S, Ishikawa E, et al. A phase I study ofα-galactosylceramide (KRN 7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2005; 11: 1910-7
|
|
|
|
|
|
13）Ishikawa E, Motohashi S, Ishikawa A, et al. Dendritic cell maturation by CD11c(-) T cells and Vα24(＋) natural killer T-cell activation by α-Galactosylceramide. Int J Cancer. 2005; 117: 265-73
|
|
|
|
|
|
14）Nieda M, Okai M, Tazbirkova A, et al. Therapeutic activation of Vα24＋Vβ11＋ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood. 2004; 103: 383-9
|
|
|
|
|
|
15）Chang DH, Osman K, Connolly J, et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosylceramide loaded mature dendritic cells in cancer patients. J Exp Med. 2005; 201: 1503-17
|
|
|
|
|
|
16）Motohashi S, Ishikawa A, Ishikawa E, et al. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res. 2006; 12: 6079-86
|
|
|
|
|